Zofran and Dyslipidaemia - a phase IV clinical study of FDA data

Summary:

Dyslipidaemia is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Dyslipidaemia when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Dyslipidaemia?

Dyslipidaemia (abnormal amount of lipids) is found to be associated with 836 drugs and 711 conditions by eHealthMe. Check the latest studies of Dyslipidaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 65 people (0.07%) have Dyslipidaemia.

Among these 65 people:

How long have people been on Zofran when they have Dyslipidaemia? *

What is the gender of people who have Dyslipidaemia when taking Zofran? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Dyslipidaemia when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Dyslipidaemia? *

Dyspnea (difficult or laboured breathing): 42 people, 64.62%
Depression: 39 people, 60.00%
Stress And Anxiety: 38 people, 58.46%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 37 people, 56.92%
Osteonecrosis Of Jaw (death of bone of jaw): 35 people, 53.85%
Back Pain: 33 people, 50.77%
Fatigue (feeling of tiredness): 33 people, 50.77%
Pain: 32 people, 49.23%
Headache (pain in head): 32 people, 49.23%
Neuropathy Peripheral (surface nerve damage): 31 people, 47.69%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 17 people, 26.15%
Multiple Myeloma (cancer of the plasma cells): 15 people, 23.08%
Bone Disorder: 13 people, 20.00%
Metastases To Bone (cancer spreads to bone): 9 people, 13.85%
Pain: 9 people, 13.85%
Neoplasm Malignant (cancer tumour): 8 people, 12.31%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 9.23%
High Blood Cholesterol: 5 people, 7.69%
Bone Loss: 5 people, 7.69%
High Blood Pressure: 4 people, 6.15%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Dyslipidaemia?

- Check whether Dyslipidaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Dyslipidaemia treatments and more:

Dyslipidaemia (42,009 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dyslipidaemia:

Dyslipidaemia (836 drugs)

Browse all the conditions that are associated with Dyslipidaemia:

Dyslipidaemia (711 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.